Novotech Strengthens Leadership with Dr. Yooni Kim
Novotech, a leading global biotech Contract Research Organization (CRO), is thrilled to announce that Dr. Yooni Kim has been appointed as the new Managing Director for the Asia-Pacific (APAC) region. This important move signifies a crucial step in Novotech's journey toward expansion and operational improvement.
The Strategic Importance of the Role
Dr. Kim's appointment is a vital component of Novotech's strategy to enhance its global reach and elevate its capabilities across various phases of clinical trials. Establishing this role is crucial in striking a balance between maintaining global consistency and being responsive to local needs. Under Dr. Kim's leadership, Novotech aims to harmonize its operations in key markets, including the United States, Europe, Mainland China, and throughout the Asia-Pacific.
Dr. Yooni Kim’s Impressive Background
Dr. Yooni Kim brings an impressive wealth of experience to this position, with over 25 years spent in clinical research across both academia and CROs, along with relevant work with pharmaceutical companies. She has been part of Novotech since 2016, initially serving as Executive Director, where she played a key role in the company's growth in Asia. Following Novotech’s successful merger with the PPC Group in 2019, Dr. Kim became the Vice President of Global Clinical Services, overseeing the company's global clinical services departments. Her work enhanced the approach to clinical trials in collaboration with stakeholders around the world. Dr. Kim holds a Bachelor of Pharmacy from Ewha Womans University and a PhD in Preventive Medicine from Seoul National University.
Dr. Kim’s Vision and Objectives
In her new role, Dr. Kim will strategize and lead Novotech's activities in the APAC region, guiding various teams to ensure excellence in all services offered. She expressed her enthusiasm for this position, stating, "I aim to bolster Novotech's capabilities in the region by being organized and attentive to our customers’ needs. Our focus will be on delivering outstanding value and service while fostering essential relationships with key opinion leaders and regulatory bodies, and enhancing collaborations across clinical trial sites." This vision is aimed at leveraging the unique strengths of the APAC region for the benefit of clients' clinical trial programs.
Significance of the APAC Region
Dr. Moller, Novotech’s CEO, emphasized that the APAC region holds great importance for Novotech’s strategic goals. By appointing a leader with Dr. Kim's extensive experience and customer-centric approach, the organization seeks to optimize operations and management in this crucial area. Ultimately, this effort is aimed at providing clients with accurate data and dependable outcomes throughout their clinical trial programs.
Future Contributions and Commitments
Dr. Kim will also become a member of Novotech’s Executive Committee, where her insights will contribute to the company's global strategies and overall vision. This appointment reaffirms Novotech's commitment to refining its organizational structure to remain an essential partner for biotech firms at every stage of therapy development.
About Novotech
Since its founding in 1997, Novotech has developed into a trusted global full-service clinical Contract Research Organization (CRO). The company specializes in partnering with biotech firms to expedite the development of groundbreaking therapeutics. With numerous accolades, including the CRO Leadership Award 2023 and the Asia-Pacific Contract Research Organization Company of the Year Award since 2006, Novotech is recognized as a leader in the industry.
Comprehensive Range of Services
Novotech provides an extensive array of services, including laboratory functions, Phase I facilities, drug development consultations, and regulatory guidance. Having worked on over 5,000 clinical projects, which range from Phase I to IV clinical trials and bioequivalence studies, Novotech stands as a reliable choice for strategic collaboration. The organization operates in 34 locations worldwide and employs over 3,000 skilled professionals.
Engagement and Expertise
For more information or to connect with an expert team member, visit the official site.
Frequently Asked Questions
1. Who is Dr. Yooni Kim?
Dr. Yooni Kim is the new Managing Director for Novotech's APAC region, bringing over 25 years of experience in clinical research.
2. What is the purpose of her appointment?
The purpose is to enhance Novotech's operational capabilities and further its global expansion within the APAC region.
3. What prior experience does Dr. Kim bring?
Dr. Kim has extensive experience across academia, CROs, and pharmaceutical companies, having held various leadership positions.
4. How will Dr. Kim's role impact Novotech's APAC operations?
This leadership transition aims to align and improve Novotech's operations, ensuring excellent results for clients involved in clinical trials.
5. What is Novotech's overarching mission?
Novotech is committed to being a strategic partner for biotech companies throughout every phase of therapeutic development.
